In recent years, the outcomes for rheumatoid arthritis (RA) have improved dramatically, thanks to the availability of biologic disease-modifying antirheumatic drugs (bDMARDs) and treat-to-target strategies.1 Further, earlier initiation of disease-modifying therapies results in better and tighter control of disease, since prompt treatment initiation induces a deeper modulation of a less mature and more reversible inflammatory process.1